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The chemical synthesis product is the amide of chlorine salicylic acid and 
sulphanilamide (5ClSA-SA). This research had as objective the effect of this product 
from salicylic acid class as a potential medicine on the serum transaminasis activity. 
5ClSA-SA has been administrated intraperitoneal to Wistar rats for 7 days 
consecutively determining ALT and AST transaminasis activities after 5 and 7 days. 
Serum transaminases had high values compared to the control sample (220% AST 
and 237% ALT).  
This synthesis product can lead to stress that induces increasing of plasmatic 
enzymes activity, transaminasis being one of those. 
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Introduction 
 
Among unsteroidal and incendiary (NSAID) drugs the most popular is the 
salicylic acid, a common component in plants. It is used from century as traditional 
drug (at first as an acetate esther, then as aspirin). The salicylic acid is important 
for other pharmaceutical products production like salicylanilides compounds [3]. 
In general, the salicylats act thru the properties of salicylic acid which is 
included in these compounds. Carboxyl or hydroxyl groups’ substitution changes 
the efficiency or toxicity of salicylat compounds [8]. The aim of this study was to 
determinate the effect of a new synthesis product, salicylic acid compound, on the 
seric aminotranspherasis activity. 
 
Materials and Methods 
 
The experiment was carried out on three months old Wistar rats divided into 
three batches: a control (C, n=7) and 2 experimental batches (E1 and E2 with equal 
number of gentry: n=5). To the experimental batches solution with 0,44 mg 5ClSA-
SA/g m.c./day was administrated intra-peritoneum, for 5 days consecutively (E1) 
respectively 7 days consecutively (E2) as for the control batch, the same quantity of   178
distilled water was administrated. Because for the new synthesis product was not 
determinate DL50, the 5ClSA-SA dose was calculated so that 0.44 mg – salicylic 
compound’s nucleus which is included in his structure – to be in amount of 1/10 
DL50 salicylanylid. 
Blood samples were taken from the cord as follows: at the begining of 3 
controls, in 24 hours after the 5th administration from E1 and one rat in control 
sample, in 24 hours after the 7th administration from E2 and another 3 rats in 
control sample. Were determinates the aminotranspherasys: alanin 
aminotranspferasys (ALT) and aspartat aminotranspferasys (AST) with Coulter 
Maxm Beckman Hematology Automatic Analyzer. 
 
Results and discussion 
 
The obtained results are presented in tables 1, 2 and graphs 1, 2. 
 
  Table 1 
Mean values of aminotranspherasys AST and ALT 
  C E1 E 2
AST 
U/I 
55±2.15 146±6.53 176±4.35 
 C  E1 E 2
ALT 
U/I 
31±0.22 60.6±3.09 73.5±1.39
 
Graph 1 
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Graph 2 
Mean values of alanin aminotranspferasys (ALT) 
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Analyzing the results obtained during this study, an increase of 
aminotranspherasys can be observed (table 1). 
AST values, after new synthesis product administration, have increased after 
5 administrations with 165% and at 24h after 7
th administration with 220% 
compared to control. 
ALT also increased with 95.5% at 24h after 5
th administration compared to 
control, respectively with 237% at 24h after 7
th administration. At control, AST 
and ALT values were in normal limits after some authors [9, 12] and were different 
after others [1, 5, 10]. 
The amplest medical practical application has ALT and AST 
aminotranspherasys. The aminotranspherasys releases depend on the hepathocytes 
enzymatic spectrum and their capacity of synthesize proteins [11]. AST: ALT ratio 
represent DeRittis coefficient. In humans, it is 1.3. Because 89% of ALT is in 
cythosol, the enzyme activity increase in serum faster and longer under noxys acute 
action (DeRittis coefficient became proper fraction). In hypercritical or longer 
lesions prevail the AST enzyme release (DeRittis coefficient is inverted)[3]. 
Our AST enzyme increase has taken to an DeRittis coefficient of 2,39 which 
revealed a liver affection determinate either by the administrated substance or by 
the products of metabolism that can induce toxically effects. Hepatotoxicity was 
indicated by the AST activity increase from plasma and the liver severs necrosis 
[4]. 
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The liver – a complex organ with multiple functions – is the most important 
target of drugs toxicity, xenobiotics and oxidative stress. Hepatotoxicity remains 
the major cause which determines the retreat of clinically used drugs [2]. 
The AST increase can be inducted by hemolytic diseases and hemolysis. The 
study regarding the eritrocitary membrane fragility as a consequence of the impact 
administrating the 5ClSA-SA product has confirmed a possible hemolitycally 
effect of the new synthesis product (paper in course of publication). 
Aminotranspherasys increase in and under the toxic effect of some drugs, but 
some of them so called “transaminite” (as in seric hyperactivity without 
morphological sublayer and known cause) that needs a careful investigation [11]. 
 
Conclusions 
 
Amide of 5 chlorsalicylic acid with sulfanilamide has determinate the 
semnificative increase of AST and ALT aminotranspherasys activity. 
The DeRittis coefficient increase due to higher aspartat aminotranspherasys 
values indicate possible hepatics affection, induced by the new synthesis product. 
The highest value of DeRittis coefficient was registered at 5ClSA-SA 
administration, during the entire experiment which can indicate possible liver 
affection. 
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Produsul de sinteză  este amida acidului clorosalicilic cu sulfanilamida (5ClSA-SA).Prin 
experimental realizat s-a urmărit efectul acestui produs, din clasa acidului salicilic, cu 
acţiune potenţial medicamentoasă, asupra activităţii aminotransferazelor  serice. S-a 
administrat produsul 5ClSA-SA la şobolani Wistar, intraperitoneal, timp de 7 zile 
consecutiv, determinându-se activităţile transaminazelor ALT şi AST, după 5 şi respective 7 
administrări. S-au inregistrat valori crescute ale aminotransferazelor serice faţă de martor 
(cu 220% AST şi respectiv cu 237 % ALT). Administrarea acestui produs de sinteză poate 
determina stresul care induce cresterea activităţii enzimelor plasmatice printre care şi a 
aminotransferazelor. 
Cuvinte cheie: şobolani, sânge, aminotransferaze, derivaţi ai acidului salicilic. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 